Overall Survival with Amivantamab-Lazertinib in EGFR-Mutated Advanced NSCLC

  • Yang, James Chih-Hsin; 
  • Lu, Shun; 
  • Hayashi, Hidetoshi; 
  • Felip, Enriqueta; 
  • Spira, Alexander I.; 
  • ... Lee, Se-Hoon; 
  • 외 50명
Citations

WEB OF SCIENCE

151

초록

Background Previous results from this phase 3 trial showed that progression-free survival among participants with previously untreated EGFR (epidermal growth factor receptor)-mutated advanced non-small-cell lung cancer (NSCLC) was significantly improved with amivantamab-lazertinib as compared with osimertinib. Results of the protocol-specified final overall survival analysis in this trial have not been reported.Methods We randomly assigned, in a 2:2:1 ratio, participants with previously untreated EGFR-mutated (exon 19 deletion or L858R substitution), locally advanced or metastatic NSCLC to receive amivantamab-lazertinib, osimertinib, or lazertinib. Overall survival (assessed in an analysis of the time from randomization to death from any cause) in the amivantamab-lazertinib group as compared with the osimertinib group was a key secondary end point. Additional end points included safety.Results A total of 429 participants each were assigned to receive amivantamab-lazertinib or osimertinib. Over a median follow-up of 37.8 months, amivantamab-lazertinib led to significantly longer overall survival than osimertinib (hazard ratio for death, 0.75; 95% confidence interval, 0.61 to 0.92; P=0.005); 3-year overall survival was 60% and 51%, respectively. At the clinical cutoff date, 38% of participants in the amivantamab-lazertinib group and 28% in the osimertinib group were still receiving the assigned treatment. Adverse events of grade 3 or higher were more common with amivantamab-lazertinib (in 80% of participants) than with osimertinib (in 52%), particularly skin-related events, venous thromboembolism, and infusion-related events; these findings were consistent with the established safety profile of each treatment. No new safety signals were observed with additional follow-up.Conclusions Amivantamab-lazertinib led to significantly longer overall survival among participants with previously untreated EGFR-mutated advanced NSCLC than osimertinib but was associated with an increased risk of adverse events of grade 3 or higher. (Funded by Janssen Research and Development; MARIPOSA ClinicalTrials.gov number, NCT04487080.) In advanced non-small-cell lung cancer with EGFR mutations, amivantamab-lazertinib led to longer overall survival than osimertinib but was associated with an increased risk of adverse events of grade 3 or higher.

키워드

CELL LUNG-CANCER; BRAIN METASTASES; PLUS LAZERTINIB; OSIMERTINIB
제목
Overall Survival with Amivantamab-Lazertinib in EGFR-Mutated Advanced NSCLC
저자
Yang, James Chih-Hsin; Lu, Shun; Hayashi, Hidetoshi; Felip, Enriqueta; Spira, Alexander I.; Girard, Nicolas; Kim, Yu Jung; Lee, Se-Hoon; Ostapenko, Yurii; Danchaivijitr, Pongwut; Liu, Baogang; Alip, Adlinda; Korbenfeld, Ernesto; Mourao Dias, Josiane; Besse, Benjamin; Passaro, Antonio; Lee, Ki-Hyeong; Xiong, Hailin; How, Soon-Hin; Cheng, Ying; Chang, Gee-Chen; Yoshioka, Hiroshige; Thomas, Michael; Nguyen, Danny; Ou, Sai-Hong Ignatius; Mukhedkar, Sanjay; Prabhash, Kumar; D'Arcangelo, Manolo; Alatorre-Alexander, Jorge; Vazquez Limon, Juan Carlos; Alves, Sara; Stroyakovskiy, Daniil; Peregudova, Marina; Sendur, Mehmet Ali Nahit; Yazici, Ozan; Califano, Raffaele; Gutierrez Calderon, Vanesa; de Marinis, Filippo; Kim, Sang-We; Gadgeel, Shirish M.; Owen, Scott; Xie, John; Sun, Tao; Mehta, Jaydeep; Venkatasubramanian, Raja; Ennis, Mariah; Fennema, Elizabeth; Daksh, Mahesh; Roshak, Amy; Man, Julie; Knoblauch, Roland E.; Bauml, Joshua M.; Baig, Mahadi; Shah, Sujay; Sethi, Seema; Cho, Byoung Chul
DOI
10.1056/NEJMoa2503001
발행일
2025-10
유형
Article
저널명
New England Journal of Medicine
권
393
호
17
페이지
1681 ~ 1693